Company Profile

VIRCHOW GROUP
Year Established : 1982
Total Assets(USD) : 500,000 to 99,999,999
Total Number of Staff : more than 1000
Main Competitive Advantages : International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Reputation,Quality Service
  • Contact Person :
  • Fax:

Virchow Group, India manufactures APIs, intermediates and Biotech FDFs. Group companies hold cGMP approvals from USFDA, KFDA, EU and CEPs. APIs include Sulfamethoxazole, Sulfanilamide, Sulfasalazine, Sulfadiazine, sulfapyridine, Trimethoprim, Telmisartan, Olmesartan, Ranitidine, Cephalosporins (Oral and Sterile), Sildenafil, Itraconazole, pregabalin, Levetiracetam.  Intermediates include 7-AVCA and GCLE.

 

BIOTECH products include recombinant biosimilars, Blood Products (Albumin, Immunoglobulin), Probiotics, Oncology and cardiovascular products, Wound care products and Hyaluronic based medical devices. Virchow also undertakes contract manufacture of injectables (PFS, BFS, PEN cartridges) and topicals

PharmaSources Customer Service